
Fate Therapeutics (FATE) Stock Forecast & Price Target
Fate Therapeutics (FATE) Analyst Ratings
Bulls say
Fate Therapeutics Inc. is recognized as a leading developer of induced pluripotent stem cell (iPSC)-derived cancer therapeutics, particularly focusing on NK and T-cell immunotherapies. The company has recently reported promising initial clinical data, demonstrating the effectiveness of its off-the-shelf CD19 CAR-T (FT819) in patients with systemic lupus erythematosus, significantly improving key disease markers without severe adverse effects. Additionally, the allogeneic nature of FT819 enhances its potential for re-dosing strategies, which positions Fate for scalable, cost-effective manufacturing and addresses critical challenges within the cellular therapeutics field.
Bears say
Fate Therapeutics Inc. faces several risks that contribute to a negative outlook on its stock, including the potential inability to demonstrate a significant clinical efficacy advantage of FT819 compared to existing CAR-T therapies. Additionally, there are concerns regarding safety and immunogenicity, which could raise alarms with regulatory agencies and impact future partnerships. The company also faces a medium-term dilution risk, further complicating its financial outlook amid mixed clinical results observed in its efficacy evaluable patients.
This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Fate Therapeutics (FATE) Analyst Forecast & Price Prediction
Start investing in Fate Therapeutics (FATE)
Order type
Buy in
Order amount
Est. shares
0 shares